Medtronic Surges 5.59% After Strong Q4 Earnings
Medtronic reported Q4 earnings that beat expectations with revenue of $9.81 billion, up 9.9% YoY, and adjusted EPS of $1.55. The company's strong heart device sales and dividend increase drove the stock's rally, despite a 230 basis point decline in operating margins. Medtronic provided FY2027 guidance of $5.90-$6.00 EPS, slightly below analyst expectations.
Medtronic (MDT) shares surged 5.59% after the medical-device maker reported fiscal Q4 2026 results that topped Wall Street estimates. Revenue rose 9.9% year over year to $9.81 billion, ahead of the $9.61 billion consensus, while non-GAAP EPS of $1.55 edged past the $1.54 estimate on robust demand for heart devices .
The beat capped Medtronic's strongest annual revenue growth in a decade, with full-year FY26 revenue of roughly $36.4 billion. The company also raised its quarterly dividend to $0.72 per share, extending a long streak of increases, even as operating margins slipped about 230 basis points on higher costs and tariffs .
Looking ahead, Medtronic guided to FY2027 non-GAAP EPS of $5.90 to $6.00 and organic revenue growth of 6.75% to 7.25%. The EPS range sat slightly below some analyst expectations, a reminder that margin recovery and tariff exposure remain the key swing factors investors will track through the coming year.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis